arrow Log In to View Account     |          

Tuesday, September 5th at 7:00 PM ET

Presenters: Theodore J. Cory, PhD, PharmD
and Anthony Podany, PharmD

This webcast will provide live credit (L) for those states requiring it.

Advances in antiretroviral therapy (ART) have transformed human immunodeficiency virus (HIV) into a chronic disease, with life expectancies in patients with HIV/Acquired Immune Deficiency Syndrome (AIDS), who receive optimal therapy, nearing that of the uninfected population. These advances have also resulted in the development of highly efficacious prophylactic agents (eg, preexposure prophylaxis [PrEP]) that are able to reduce the risk of HIV acquisition in high-risk populations by more than 90%. However, there are pharmacological challenges in managing ART and implementing novel PrEP in an aging HIV population as this population oftentimes has multiple comorbidities that require concomitant medications. As drug therapy experts and clinicians with frequent patient contact, pharmacists are ideally suited to fulfill the growing needs related to HIV prevention and life-long treatment management for this patient population. Through interactive case-based presentations and expert discussion, this live webcast will review the advances in the management of patients with HIV/AIDS. Specifically, this will address efficacy, safety, and patient eligibility for PrEP, as well as strategies to manage adherence issues, adverse events, and drug-drug interactions.

The goal of this activity is to provide pharmacists with the most up-to-date treatment strategies to optimize management and improve outcomes for patients with or at risk for acquiring HIV.

This activity is designed community pharmacists, specialty pharmacists, infectious disease pharmacists, health systems pharmacists, managed care pharmacists and other pharmacists involved in the treatment of patients with HIV. No prerequisites required.

  • Activity Overview and Goals
  • HIV/AIDS Goals:
    The Critical Role of the Pharmacist in the Continuum of Care
  • Attaining HIV Goals:
    Improving Pharmacological Management and Treatment Success
  • Attaining HIV Goals:
    Preventing HIV Acquisition
  • Pharmacist-Derived Strategies to Overcome Barriers to Care
  • Conclusions
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
  • DESCRIBE PrEP as a method to prevent HIV acquisition, including efficacy, safety, and candidate eligibility.
  • ASSESS strategies to manage ART, including initiation, agent selection and modifications, in patients with comorbid medical and/or substance abuse conditions.
  • EVALUATE methods to identify and manage DDIs, AEs, and medication errors within ART regimens.
  • IMPLEMENT pharmacist-driven strategies to assist patients overcome structural, social and medical barriers to increase screening, prevention, and adherence to HIV therapy.
Theodore J. Cory, PhD, PharmD
Assistant Professor
Department of Clinical Pharmacy
University of Tennessee Health Sciences Center
Memphis, Tennessee

Anthony Podany, PharmD
Assistant Professor
Antiviral Pharmacology Laboratory
University of Nebraska Medical Center College of Pharmacy
Omaha, Nebraska

acpe logoThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based activity will provide a statement for 1.5 live contact hours of credit (0.15 CEUs). Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the activity; 3) completing the self-assessment instrument with a score of at least 70%. A statement of CE credit will available for download following successful completion of the educational activity. UAN: 0064-0000-17-218-L02-P. CE credit will be submitted to the NABP CPE Monitor within 30 days. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted..

NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website:
To receive credit for your participation in this activity, all pharmacists must include their CORRECT NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE-Monitor.

It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the presentations.

A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or coprovided by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

There is no fee for this educational activity.

<img src="" alt="procced to pretest" border="0" />
University of Tennessee Advanced Studies in Pharmacy (ISSN-1558-0350), is published by ASiM CE, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC.